Ignite Creation Date:
2025-12-24 @ 5:34 PM
Ignite Modification Date:
2026-01-24 @ 6:23 AM
Study NCT ID:
NCT03822468
Status:
COMPLETED
Last Update Posted:
2025-10-16
First Post:
2019-01-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Breast Cancer (BC) | View |
| None | hormone receptor (HR) | View |
| None | HR-positive | View |
| None | human epidermal growth factor receptor 2 (HER2) | View |
| None | HER2-negative | View |
| None | ER-positive | View |
| None | advanced breast cancer (aBC) | View |
| None | ribociclib (LEE011) | View |
| None | premenopausal | View |
| None | postmenopausal | View |